Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

Monday, February 12, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has secured an initial cash payment of $7.5 million and an equity investment from TG Therapeutics. This funding is aimed at advancing the development of Azel-Cel, a treatment for autoimmune diseases. The collaboration leverages Precision's ARCUS platform for gene editing therapies.
Price reaction · baseline $11.52 (2024-02-09 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences received a significant cash payment of $7.5 million.
  • The investment from TG Therapeutics supports the development of Azel-Cel.
  • The collaboration focuses on innovative treatments for autoimmune diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Feb. 12, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

What is the amount of the investment from TG Therapeutics?

TG Therapeutics has invested an initial $7.5 million in Precision BioSciences.

What is the focus of the collaboration between the two companies?

The collaboration focuses on developing Azel-Cel for treating autoimmune diseases.

What platform does Precision BioSciences use for gene editing?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences TG Therapeutics Azel-Cel autoimmune diseases gene editing
Last updated: Feb 12, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →